4-(十八烷酰氨基)丁酸 | 104086-75-1

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 中文名称: 4-(十八烷酰氨基)丁酸
• 英文名称: 2',3'-dideoxycytidine-5'-diphosphate
• 英文别名: cytidine-5'-diphosphate；2',3'-Dideoxycytosine-5'-Diphosphate；[(2S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate
• CAS: 104086-75-1
• 化学式: C₉H₁₅N₃O₉P₂
• 分子量: 371.18
• InChiKey: FVSQWXITYSICAK-POYBYMJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  181
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Prodrugs Activated by Rna-Dependent Dna-Polymerases
  申请人：Bertini Ivano

  公开号：US20080300215A1

  公开（公告）日：2008-12-04

  Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.

  本发明描述了由RNA依赖的DNA聚合酶（如端粒酶和逆转录病毒酶）激活的前药，它们用于治疗血液肿瘤以及受逆转录病毒感染的患者的血液和血液衍生物，并用于制备药物组合物，用于治疗实体肿瘤、癌前状态和由逆转录病毒感染引起的疾病。
• Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
  申请人：COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE)

  公开号：EP0517986A1

  公开（公告）日：1992-12-16

  The invention relates to compositions comprising transformed erythrocytes containing phosphorylated compounds, which do not naturally occur in a human or animal organism, said compounds having the properties of: inhibiting the reverse transcriptase, and being stable in erythrocytes. The compositions of the invention are useful for the treatment of pathologies caused by the infection of a human or an animal by RNA type virus.

  本发明涉及由含有磷酸化化合物的转化红细胞组成的组合物，磷酸化化合物在人类或动物机体中并不自然存在，所述化合物具有以下特性： 抑制逆转录酶，以及 在红细胞中稳定。 本发明的组合物可用于治疗人或动物感染 RNA 型病毒后引起的病症。
• Anti-retroviral agents and delivery systems for the same
  申请人：THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce

  公开号：EP0286418B1

  公开（公告）日：1992-07-08
• ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B
  申请人：VICAL, INC.

  公开号：EP0594677A1

  公开（公告）日：1994-05-04
• EP0594677A4
  申请人：——

  公开号：EP0594677A4

  公开（公告）日：1997-09-17